康诺生物递表港交所

Group 1 - The core viewpoint of the news is that Kangnuo Biopharmaceutical Co., Ltd. has submitted a listing application to the Hong Kong Stock Exchange, with Guotou Securities International as its sole sponsor [1] - Kangnuo Biopharmaceutical focuses on mitochondrial medicine and health products, covering research and development, drug production, and commercialization [1] - The company is primarily researching diseases caused by mitochondrial dysfunction and aims to apply NAD+ in the fields of cardiovascular diseases, neurodegenerative diseases, reproductive health, and aging [1] Group 2 - The company is registered in the People's Republic of China and operates as a joint-stock company [2] - The listing will involve H shares, with the number of shares depending on the exercise of options [3] - The maximum price for each H share is set in Hong Kong dollars, with additional fees including a brokerage commission and various transaction fees [3]